oncology

News in brief: HCV cure doubles survival in HCC; COVID-19 boosts confidence in home-based care; Surprise response to aromatase inhibitor in rare uterine cancer

DAAs the gateway drug to better liver cancer survival  Patients with HCV-related liver cancer who have achieved HCV cure before their cancer diagnosis have improved overall survival compared with patients who are viraemic at diagnosis. An Australian study of 422 patients with HCV-related hepatocellular carcinoma (HCC) found five-year overall survival was 51% in those who ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic